Glovadalen

Last updated

Glovadalen
Glovadalen.svg
Clinical data
Other namesUCB-0022; UCB0022
Identifiers
  • 2-(3,5-dichloro-1-methylindazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C24H27Cl2N3O3
Molar mass 476.40 g·mol−1
3D model (JSmol)
  • C[C@H]1C2=C(C[C@@H](N1C(=O)CC3=C(C=CC4=C3C(=NN4C)Cl)Cl)CO)C(=CC=C2)C(C)(C)O
  • InChI=1S/C24H27Cl2N3O3/c1-13-15-6-5-7-18(24(2,3)32)16(15)10-14(12-30)29(13)21(31)11-17-19(25)8-9-20-22(17)23(26)27-28(20)4/h5-9,13-14,30,32H,10-12H2,1-4H3/t13-,14+/m0/s1
  • Key:SVTDEVFVOSMAQQ-UONOGXRCSA-N

Glovadalen (developmental code name UCB-0022) is a dopamine D1 receptor positive allosteric modulator which is under development for the treatment of Parkinson's disease. [1] [2] [3] [4] [5] [6] It has been found to potentiate the capacity of dopamine to activate the D1 receptor by 10-fold in vitro with no actions on other dopamine receptors. [5] [6] As of May 2024, glovadalen is in phase 2 clinical trials for this indication. [1] [2] [5] The drug is under development by UCB Biopharma. [1] [4] [5] It is described as an orally active, centrally penetrant small molecule. [1] [5] [6]

See also

References

  1. 1 2 3 4 "UCB 0022". AdisInsight. Springer Nature Switzerland AG. 28 May 2024. Retrieved 10 August 2024.
  2. 1 2 "Delving into the Latest Updates on Glovadalen with Synapse". Synapse. 8 August 2024. Retrieved 10 August 2024.
  3. ↑ McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, et al. (2023). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update". Journal of Parkinson's Disease. 13 (4): 427–439. doi:10.3233/JPD-239901. PMC   10357160 . PMID   37302040. Our analysis of dopaminergic therapies shows a continued emphasis on DA agonists and levodopa reformulation. These include Cerevel's tavapadon, a D1/D5 receptor partial agonist and UCB0022, a positive allosteric modulator of the D1 receptor, as well as approaches to sub-cutaneously deliver levodopa/carbidopa such as Abbvie's ABBV-951 and Neuroderm's ND0612.
  4. 1 2 "Glovadalen". IUPHAR/BPS Guide to PHARMACOLOGY. Retrieved 10 August 2024.
  5. 1 2 3 4 5 "UCB0022". ALZFORUM. 3 May 2024. Retrieved 10 August 2024.
  6. 1 2 3 Vermeiren C, Ates A, Bouzom F, Delaunois A, Gillard M, Kenda B, et al. (7 September 2022). "Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)". Movement Disorders. 37 (Suppl 2 [2022 International Congress September 15-18, 2022. Madrid, Spain]). Retrieved 10 August 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.